If you'd looked a little more into competitors during the run up of IMU, you'd have made some cash instead of sitting in the red now. Plenty of smart people saw the signs. You can't provide meaningful commentary about competitors because you don't have the skillset, which is evidenced by your posting history boasting buys. For example, there are significantly more competitors for CF33 that have finished P1 clinical trials than there are for Bisantrene. None of those drugs are approved, but you continued to buy IMU when HER-Vaxx had failed and CF33 was in the clinic with poor preclinical data supporting it.
Show me a drug that provides cardioprotection while also providing clinically meaningful anti-cancer efficacy in humans. 1 drug. Anywhere. Ever.
Proof of cardioprotection in humans translates to 65 clinical trials highlighting the safety and efficacy of the worlds first cardioprotective anti-cancer drug, Bisantrene.
Cardioprotection thread, page-669
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |